Relationship between plasma circulating cell-free DNA concentration and treatment outcomes including prognosis in patients with advanced non-small cell lung cancer
Open Access
- 14 September 2023
- journal article
- research article
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 23 (1) , 1-9
Abstract
Background: Some research found that elevated plasma cell-free DNA (cfDNA) concentrations and poor prognosis are associated in non-small cell lung cancer (NSCLC). However, more studies need to be carried out to verify this conclusion. Therefore, this study investigated the relationship between cfDNA concentration and treatment outcomes including prognosis in patients with advanced NSCLC. Methods: We retrospectively collected medical records and cfDNA data from 160 patients with advanced NSCLC. Progression-free survival (PFS) were calculated using the Kaplan-Meier method and were compared between groups using the log rank test. Cox regression analysis was used for estimating the independent predictors of PFS. And we used logistic regression to evaluate the relationship between baseline biomarkers and efficacy. In our study, BT1 cfDNA, BT2 cfDNA, and BT3 cfDNA were defined as cfDNA concentration before the first treatment (baseline cfDNA concentration), cfDNA concentration before the second treatment, and cfDNA concentration before the third treatment, respectively. Results: Patients with low cfDNA (BT1 cfDNA < 15 (ng/mL)) were reported a significantly prolonged median progression-free survival (mPFS) compared with patients with patients with high cfDNA (BT1 cfDNA ≥ 15(ng/mL)) (mPFS: 14.6 vs. 8.3 months, P = 0.002), as well as patients with neutrophil/lymphocyte ratio (NLR)P = 0.023). In addition, Cox proportional hazards regression analysis identified independent indicators associated with PFS including BT1 cfDNA ≥ 15 (ng/mL), NLR ≥ 2.98 and extrapulmonary metastasis. The best cut-off value for BT3 cfDNA for predicting disease progression is 41.46 (ng/mL) (Area Under the Curve (AUC): 0.652, 95%CI: 0.516–0.788), achieving 90.7% sensitivity and 37.5% specificity for the prediction of disease progression. BT3 cfDNA (OR = 6.08, 95% CI: 1.94–19.57, P = 0.002) was an independent factor for disease progression in patients with advanced NSCLC. Conclusions: BT1 cfDNA may be a biomarker to assess the prognosis of advanced NSCLC. Patients with advanced NSCLC with lower cfDNA and NLR before treatment had a better prognosis. Increased BT3 cfDNA concentration was an independent factor of disease progression in advanced NSCLC patients. These findings may assist in identifying high-risk patients and guiding treatment strategies.Keywords
Funding Information
- National Natural Science Foundation of China (82273162)
This publication has 38 references indexed in Scilit:
- The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancerLung Cancer, 2013
- The value of serial plasma nuclear and mitochondrial DNA levels in patients with acute ischemic strokeClinica Chimica Acta, 2011
- Circulating DNA is a Useful Prognostic Factor in Patients with Advanced Non-small Cell Lung CancerJournal of Thoracic Oncology, 2011
- Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancerLung Cancer, 2010
- Serial Assessment of Human Tumor Burdens in Mice by the Analysis of Circulating DNACancer Research, 2007
- Circulating Deoxyribonucleic Acid As Prognostic Marker in Non–Small-Cell Lung Cancer Patients Undergoing ChemotherapyJournal of Clinical Oncology, 2004
- Plasma DNA microsatellite panel as sensitive and tumor‐specific marker in lung cancer patientsInternational Journal of Cancer, 2003
- Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumoursCancer Letters, 1995
- Second-Strength PPD Test (Cont.)New England Journal of Medicine, 1971
- Zoster-like Disease in Infants and Young ChildrenNew England Journal of Medicine, 1971